Prostate Cancer

Collaboration focused on second-generation oncolytic virus therapies

Published in Gene Therapy Weekly, January 16th, 2003

Cell Genesys, Inc., (CEGE) announced that it has entered into a 3-year research collaboration with VectorLogics, Inc., in which Cell Genesys' oncolytic virus therapies will be evaluated in combination with novel methods to further enhance the viruses' cell targeting abilities.

The methods, developed by David T. Curiel, MD, founder of VectorLogics and professor and head of the Gene Therapy Center at the University of Alabama, involve the modification of structures located on the surface of the oncolytic virus that play a key role in directing the viruses to target, penetrate, and ultimately destroy cancer cells. Financial terms of the collaboration were not...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2003-01-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry